ReviewJournal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology2020
Dopaminergic Pathways in Obesity-Associated Inflammation.
Review in Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Physical activity interventions for cardiopulmonary fitness in obese children and adolescents: a systematic review and meta-analysis.BMC pediatrics · 2023Pooled it
- Beyond Pleasure: Unraveling the Multifaceted Role of Dopamine in Obesity and Metabolic Regulation.Current obesity reports · 2026Review
- ICU Admission and Post-Discharge Mortality in COVID-19: Different Risk Factors Across Clinical Phases.Medical sciences (Basel, Switzerland) · 2026Observational
- Obesity-induced metabolic reprogramming of the tumor immune microenvironment: mechanisms, spatial niches, and immunotherapy response.Frontiers in immunology · 2026Review
- Understanding the Pre-Clinical Stages of Parkinson's Disease: Where Are We in Clinical and Research Settings?International journal of molecular sciences · 2025Review
- Exercise orchestrates systemic metabolic and neuroimmune homeostasis via the brain-muscle-liver axis to slow down aging and neurodegeneration: a narrative review.European journal of medical research · 2025Review
- Progress in research on nutrition, neuroinflammation and dopaminergic alterations in Tic disorders.Frontiers in pediatrics · 2025Review
- Self-management behaviours in adults with non-alcoholic fatty liver disease: a cross-sectional survey from China.BMJ open · 2024Article
- Body and mind: how obesity triggers neuropsychiatric and neurodegenerative disorders.Frontiers in psychiatry · 2024Article
- Anti-Inflammatory Effects of Peripheral Dopamine.International journal of molecular sciences · 2023Review
- Inflammation, Dopaminergic Brain and Bilirubin.International journal of molecular sciences · 2023Review
- Clinical characteristics of male prolactinoma patients mainly presenting with severe obesity and the metabolic response to dopamine agonist therapy.Frontiers in endocrinology · 2023Article
- Bromocriptine-QR Therapy Reduces Sympathetic Tone and Ameliorates a Pro-Oxidative/Pro-Inflammatory Phenotype in Peripheral Blood Mononuclear Cells and Plasma of Type 2 Diabetes Subjects.International journal of molecular sciences · 2022Article
- The role of hypothalamic endoplasmic reticulum stress in schizophrenia and antipsychotic-induced weight gain: A narrative review.Frontiers in neuroscience · 2022Review
- A new experimental design to study inflammation-related versus non-inflammation-related depression in mice.Journal of neuroinflammation · 2021Article
- Cardiorespiratory fitness in children with overweight/obesity: Insights into the molecular mechanisms.Scandinavian journal of medicine & science in sports · 2021Article
- Nucleus accumbens microstructure mediates the relationship between obesity and eating behavior in adults.Obesity (Silver Spring, Md.) · 2021Article
- Analysis of miRNAs Profiles in Serum of Patients With Steatosis and Steatohepatitis.Frontiers in cell and developmental biology · 2021Article
- Divergent Nodes of Non-autonomous UPRCell reports · 2020Article
- Dopaminergic and Adrenergic Pathways as Targets for Drug Repurposing in the Neuroimmune Network.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The overwhelming prevalence of obesity is a priority for public health compromising human lifespan and representing important economic burden worldwide. Obesity is characterized by a state of chronic low-grade inflammation associated to metabolic dysfunction. Although the efforts for unravelling the complex immunometabolic signaling pathways to explain the association of obesity with type 2 diabetes, cardiovascular diseases, cancer, neurodegenerative diseases and psychiatric disorders, we still do not have all the picture to design effective therapeutic to fight these immunometabolic disease clusters. Dopaminergic pathways apart from having a major role in the regulation of appetite and feeding behaviors are important immunoregulators in inflammation; thus, dopaminergic regulation is suggested to impact obesity- associated inflammation. Dopamine (DA) has been reported to modulate immune function and immune cells themselves produce endogenous DA. DA-induced immunomodulation is currently the focus of intense experimental research and dopaminergic pathways are increasingly considered a target for drug development in immune diseases. While the role of dopaminergic pathways in immune-mediated diseases has been intensively investigated in neurodegenerative diseases, dopaminergic immunomodulation in obesity-associated inflammation is largely unknown. This review will integrate the actual knowledge about dopaminergic pathways involved in obesity-associated inflammation with special focus on immune innate key cell players. We present an explanatory hypothesis with a model that integrate central and peripheral dopaminergic circuits in the relationship between neuroimmune and metabolic systems in obesity-associated inflammation. A perspective on the potential role of dopaminergic drugs in the context of obesity will be given. Graphical Abstract Graphical representation of central and peripheral dopaminergic pathways in obesity-associated inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.